Poster No:
1926
Submission Type:
Abstract Submission
Authors:
Marissa Holden1, Isabella Premoli2, Scott Clark3, Nigel Rogasch4, Mitchell Goldsworthy5
Institutions:
1Adelaide University, Adelaide, FM, 2Synendos Therapeutics AG., Basel, Basel, 3Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, 4School of Biomedicine, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, 51. School of Biomedicine, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia
First Author:
Co-Author(s):
Scott Clark
Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide
Adelaide, South Australia
Nigel Rogasch
School of Biomedicine, Faculty of Health and Medical Sciences, University of Adelaide
Adelaide, South Australia
Mitchell Goldsworthy
1. School of Biomedicine, Faculty of Health and Medical Sciences, University of Adelaide
Adelaide, South Australia
Introduction:
EEG signals contain both periodic (i.e., oscillatory) and aperiodic (i.e., non-oscillatory) components. Aperiodic activity results in the 1/f-like background of the EEG power spectrum and can be quantified by fitting a model to the spectra with parameters for offset and steepness of the slope (i.e., 1/f exponent).
Computational modelling and GABAergic drug studies show that increased inhibitory input leads to a steeper slope (higher exponent). The aim of this study was to quantify the effect of two antiepileptic drugs (AEDs) which reduce cortical excitability on properties of aperiodic EEG activity.
Methods:
Resting EEG data with eyes open and closed were collected from 15 healthy male volunteers at baseline and 2 hours post-administration of Lamotrigine (300 mg), Levetiracetam (3000 mg), or placebo. EEG data were processed in MATLAB, and power spectra were calculated using Welch's method. Aperiodic fits were performed using the specparam algorithm in Python, with goodness-of-fit metrics and visual inspection to ensure model accuracy.
Results:
In the eyes-open, but not eyes-closed condition, Lamotrigine administration reduced the aperiodic offset pre to post drug intake (p = 0.022, i.e., less power in low frequencies), a change which was stronger when compared to the placebo condition (p = 0.0032). There were no significant changes in exponent values during eyes-open or eyes-closed conditions, or in any parameters following Levetiracetam intake.
Conclusions:
Our findings suggest that altering cortical excitability with AEDs can reduce the aperiodic offset in EEG activity under certain conditions.
Novel Imaging Acquisition Methods:
EEG 1
Physiology, Metabolism and Neurotransmission:
Neurophysiology of Imaging Signals
Pharmacology and Neurotransmission 2
Keywords:
Electroencephaolography (EEG)
1|2Indicates the priority used for review
By submitting your proposal, you grant permission for the Organization for Human Brain Mapping (OHBM) to distribute your work in any format, including video, audio print and electronic text through OHBM OnDemand, social media channels, the OHBM website, or other electronic publications and media.
I accept
The Open Science Special Interest Group (OSSIG) is introducing a reproducibility challenge for OHBM 2025. This new initiative aims to enhance the reproducibility of scientific results and foster collaborations between labs. Teams will consist of a “source” party and a “reproducing” party, and will be evaluated on the success of their replication, the openness of the source work, and additional deliverables. Click here for more information.
Propose your OHBM abstract(s) as source work for future OHBM meetings by selecting one of the following options:
I am submitting this abstract as an original work to be reproduced. I am available to be the “source party” in an upcoming team and consent to have this work listed on the OSSIG website. I agree to be contacted by OSSIG regarding the challenge and may share data used in this abstract with another team.
Please indicate below if your study was a "resting state" or "task-activation” study.
Resting state
Healthy subjects only or patients (note that patient studies may also involve healthy subjects):
Healthy subjects
Was this research conducted in the United States?
No
Were any human subjects research approved by the relevant Institutional Review Board or ethics panel?
NOTE: Any human subjects studies without IRB approval will be automatically rejected.
Yes
Were any animal research approved by the relevant IACUC or other animal research panel?
NOTE: Any animal studies without IACUC approval will be automatically rejected.
Not applicable
Please indicate which methods were used in your research:
EEG/ERP
Which processing packages did you use for your study?
Other, Please list
-
MATLAB, python, FOOOF / specparam
Provide references using APA citation style.
Authors: Marissa M. Holden 1,2, Isabella Premoli3, Scott R. Clark4, Nigel C. Rogasch1,2,5*, and Mitchell R. Goldsworthy
1. School of Biomedicine, Faculty of Health and Medical Sciences, University of Adelaide.
2. Hopwood Centre for Neurobiology, Lifelong Health Theme, South Australian Health and Medical Research Institute
3. Synendos Therapeutics AG.
4. Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide.
5. Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University
6. Behaviour-Brain-Body Research Centre, Justice and Society, University of South Australia
No